Novartis and IBM form breast cancer research partnership

pharmafile | June 7, 2017 | News story | Research and Development Novartis, ibm 

Novartis is to join forces with tech giant IBM and its Watson Health platform to tackle advanced breast cancer with an outcome-based initiative, it has emerged.

The union plans to bring together Novartis’ expertise in the breast cancer sphere with IBM Watson’s data analytics and machine learning power to calculate improved treatment outcomes for patients. The effort will be primarily based on real-world data to better our understanding of the disease, utilising IBM Watson immense processing power and AI, delivered via the cloud, to understand complex problems and respond with evidence-based answers.

IBM Watson can then consolidate and provide a breadth of real-world outcomes on subsets of patients for clinicians and oncologists can utilise.

Advertisement

IBM Watson Health Chief Medical Informatics Officer Anil Jain explained: “At Watson Health, we are tackling some of the world’s greatest challenges at the nexus of science and data, and we are proud to work with Novartis to better individualise advanced breast cancer treatment approaches in an effort to enhance patient care.”

Novartis Oncology CEO Bruno Strigini added: “Through this collaboration with IBM Watson Health, we will use real-world breast cancer data and cognitive computing to identify solutions that may help physicians better understand which therapy may be best for which patients or advise clinical practice guidelines, with the goal of improving patient outcomes and experiences.”

Matt Fellows

Related Content

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

Mosquito image

First malaria medicine for infants under 4.5kg receives approval

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …

The Gateway to Local Adoption Series

Latest content